A national multicenter study on 1072 DCIS patients treated with breast-conserving surgery and whole breast radiotherapy (COBCG-01 study).


Journal

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
ISSN: 1879-0887
Titre abrégé: Radiother Oncol
Pays: Ireland
ID NLM: 8407192

Informations de publication

Date de publication:
02 2019
Historique:
received: 05 05 2018
revised: 17 07 2018
accepted: 18 07 2018
pubmed: 5 8 2018
medline: 14 1 2020
entrez: 5 8 2018
Statut: ppublish

Résumé

Breast-conserving surgery (BCS) and whole breast radiation (RT) with or without endocrine therapy (ET) represent the standard of care for ductal carcinoma in situ (DCIS). The use of adjuvant treatments after surgery is still controversial in this setting. We performed a retrospective multicenter analysis on a series of DCIS patients treated with BCS and adjuvant RT. We collected clinical data from nine Italian centers on 1072 women having a diagnosis of DCIS and treated between 1997 and 2012. We reported on the 5- and 10-year local recurrence (LR) rates, overall survival, and breast cancer specific survival (BCSS) employing the Kaplan-Meier method. At a median follow-up of 8.4 years, 67 LR (6.3%) and 47 deaths (4.4%) were observed. LR rates at 5 and 10 years were 3.4% and 7.6%, respectively. BCSS rates at 5 and 10 years were 99.7% and 99.1%, respectively. At univariate regression analysis, postmenopausal state (p = 0.009), estrogen receptor (ER) (p = 0.0001) and progesterone receptor (p = 0.018) positivity and ET (p = 0.006) were inversely correlated with LR. Final surgical margins (FSM) status <1 mm was significantly correlated with higher LR (p = 0.003). At multivariate regression analysis postmenopausal state (p = 0.03), and ER positive (p = 0.045) maintained the significant favorable feature, while FSM <1 mm (p = 0.024) confirmed its negative impact on LR. Our real-life study pointed out the significant favorable prognostic role of postmenopausal state and ER positive status on LR occurrence. FSM <1 mm was significantly correlated to a higher chance to experience LR.

Sections du résumé

BACKGROUND AND PURPOSE
Breast-conserving surgery (BCS) and whole breast radiation (RT) with or without endocrine therapy (ET) represent the standard of care for ductal carcinoma in situ (DCIS). The use of adjuvant treatments after surgery is still controversial in this setting. We performed a retrospective multicenter analysis on a series of DCIS patients treated with BCS and adjuvant RT.
MATERIALS AND METHODS
We collected clinical data from nine Italian centers on 1072 women having a diagnosis of DCIS and treated between 1997 and 2012. We reported on the 5- and 10-year local recurrence (LR) rates, overall survival, and breast cancer specific survival (BCSS) employing the Kaplan-Meier method.
RESULTS
At a median follow-up of 8.4 years, 67 LR (6.3%) and 47 deaths (4.4%) were observed. LR rates at 5 and 10 years were 3.4% and 7.6%, respectively. BCSS rates at 5 and 10 years were 99.7% and 99.1%, respectively. At univariate regression analysis, postmenopausal state (p = 0.009), estrogen receptor (ER) (p = 0.0001) and progesterone receptor (p = 0.018) positivity and ET (p = 0.006) were inversely correlated with LR. Final surgical margins (FSM) status <1 mm was significantly correlated with higher LR (p = 0.003). At multivariate regression analysis postmenopausal state (p = 0.03), and ER positive (p = 0.045) maintained the significant favorable feature, while FSM <1 mm (p = 0.024) confirmed its negative impact on LR.
CONCLUSIONS
Our real-life study pointed out the significant favorable prognostic role of postmenopausal state and ER positive status on LR occurrence. FSM <1 mm was significantly correlated to a higher chance to experience LR.

Identifiants

pubmed: 30075864
pii: S0167-8140(18)33414-5
doi: 10.1016/j.radonc.2018.07.015
pii:
doi:

Substances chimiques

Antineoplastic Agents, Hormonal 0
Receptors, Estrogen 0
Receptors, Progesterone 0

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

208-214

Informations de copyright

Copyright © 2018 Elsevier B.V. All rights reserved.

Auteurs

Icro Meattini (I)

Azienda Ospedaliero Universitaria Careggi - University of Florence, Radiation Oncology Unit, Florence, Italy; Clinical Oncology Breast Cancer Group (COBCG), Italy. Electronic address: icro.meattini@unifi.it.

Nadia Pasinetti (N)

Radiation Oncology Department, Brescia University and Spedali Civili, Brescia, Italy; Clinical Oncology Breast Cancer Group (COBCG), Italy.

Bruno Meduri (B)

University Hospital of Modena, Radiation Oncology Unit, Italy; Clinical Oncology Breast Cancer Group (COBCG), Italy.

Fiorenza De Rose (F)

Radiotherapy and Radiosurgery Department, Humanitas Cancer Center and Research Hospital, Rozzano, Italy; Clinical Oncology Breast Cancer Group (COBCG), Italy.

Maria Carmen De Santis (MC)

National Cancer Institute of Milan, Italy; Clinical Oncology Breast Cancer Group (COBCG), Italy.

Pierfrancesco Franco (P)

University of Turin, Department of Oncology - Radiation Oncology, Italy; Clinical Oncology Breast Cancer Group (COBCG), Italy.

Valentina Lancellotta (V)

University of Perugia and Perugia General Hospital, Radiation Oncology Section, Italy; Clinical Oncology Breast Cancer Group (COBCG), Italy.

Francesca Rossi (F)

Azienda USL Toscana Centro, Radiotherapy Unit, Florence, Italy.

Calogero Saieva (C)

Institute for Cancer Research, Prevention and Clinical Network (ISPRO), Florence, Italy.

Isacco Desideri (I)

Azienda Ospedaliero Universitaria Careggi - University of Florence, Radiation Oncology Unit, Florence, Italy; Clinical Oncology Breast Cancer Group (COBCG), Italy.

Camilla Delli Paoli (C)

Azienda Ospedaliero Universitaria Careggi - University of Florence, Radiation Oncology Unit, Florence, Italy.

Elisa D'Angelo (E)

University Hospital of Modena, Radiation Oncology Unit, Italy.

Luca Triggiani (L)

Radiation Oncology Department, Brescia University and Spedali Civili, Brescia, Italy.

Paolo Bastiani (P)

Azienda USL Toscana Centro, Radiotherapy Unit, Florence, Italy.

Filippo Alongi (F)

Sacro Cuore Don Calabria Hospital, Verona, Italy; University of Brescia, Italy.

Laura Lozza (L)

National Cancer Institute of Milan, Italy.

Cynthia Aristei (C)

University of Perugia and Perugia General Hospital, Radiation Oncology Section, Italy.

Umberto Ricardi (U)

University of Turin, Department of Oncology - Radiation Oncology, Italy.

Marta Scorsetti (M)

Radiotherapy and Radiosurgery Department, Humanitas Cancer Center and Research Hospital, Rozzano, Italy; Department of Biomedical Sciences, Humanitas University, Rozzano, Italy.

Lorenzo Livi (L)

Azienda Ospedaliero Universitaria Careggi - University of Florence, Radiation Oncology Unit, Florence, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH